How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-with-somatostatin-analogue-octreotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

combination with somatostatin analogue octreotide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

combination with somatostatin analogue octreotide (combination with somatostatin analogue octreotide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin analogue. Area: Oncology.

marketed Somatostatin analogue Somatostatin receptors (SSTR2, SSTR5) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

combination with somatostatin analogue octreotide (combination with somatostatin analogue octreotide) — Ludwig-Maximilians - University of Munich. Octreotide is a somatostatin analogue that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
combination with somatostatin analogue octreotide TARGET	combination with somatostatin analogue octreotide	Ludwig-Maximilians - University of Munich	marketed	Somatostatin analogue	Somatostatin receptors (SSTR2, SSTR5)
Placebo lanreotide	Placebo lanreotide	University Hospital, Limoges	phase 3	Somatostatin analogue	Somatostatin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Somatostatin analogue class)

Ludwig-Maximilians - University of Munich · 1 drug in this class
University Hospital, Limoges · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). combination with somatostatin analogue octreotide — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-with-somatostatin-analogue-octreotide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab